TR200301552A1 - Novel oral pharmacological formulations of rofecoxib. - Google Patents
Novel oral pharmacological formulations of rofecoxib.Info
- Publication number
- TR200301552A1 TR200301552A1 TR2003/01552A TR200301552A TR200301552A1 TR 200301552 A1 TR200301552 A1 TR 200301552A1 TR 2003/01552 A TR2003/01552 A TR 2003/01552A TR 200301552 A TR200301552 A TR 200301552A TR 200301552 A1 TR200301552 A1 TR 200301552A1
- Authority
- TR
- Turkey
- Prior art keywords
- rofecoxib
- novel oral
- pharmacological formulations
- oral pharmacological
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Bu buluş rofekoksib etken içeren ve bu etken maddenin oral yolla alınmasını sağlayan yeni farmasötik dozaj formlarını hazırlamak için geliştirilen yeni yöntem ile ilgilidir. Geliştirilen bu formülasyon ile rofekoksibin dissolüsyon ve invivo özelliklerine üstünlük kazandırılmıştır.The present invention relates to a novel method for preparing novel pharmaceutical dosage forms comprising rofecoxib agent and for oral administration thereof. With this formulation developed, dissolution and invivo properties of rofecoxib were improved.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2003/01552A TR200301552A1 (en) | 2003-09-18 | 2003-09-18 | Novel oral pharmacological formulations of rofecoxib. |
PCT/TR2004/000039 WO2005025564A1 (en) | 2003-09-18 | 2004-09-16 | Oral pharmaceutical formulations of rofecoxib |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2003/01552A TR200301552A1 (en) | 2003-09-18 | 2003-09-18 | Novel oral pharmacological formulations of rofecoxib. |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200301552A1 true TR200301552A1 (en) | 2005-10-21 |
Family
ID=34311481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2003/01552A TR200301552A1 (en) | 2003-09-18 | 2003-09-18 | Novel oral pharmacological formulations of rofecoxib. |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR200301552A1 (en) |
WO (1) | WO2005025564A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3883562A4 (en) | 2018-11-21 | 2022-08-03 | Tremeau Pharmaceuticals, Inc. | Purified forms of rofecoxib, methods of manufacture and use |
US10945992B1 (en) * | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP9902889A3 (en) * | 1996-05-17 | 2002-04-29 | Merck Frosst Canada & Co Kirkl | The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments |
JP2003523954A (en) * | 1999-12-08 | 2003-08-12 | ファルマシア コーポレイション | Cyclooxygenase-2 inhibitor composition with rapid onset of therapeutic effect |
PL363771A1 (en) * | 2001-02-27 | 2004-11-29 | Ranbaxy Laboratories Limited | Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
WO2003086343A2 (en) * | 2002-04-05 | 2003-10-23 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
-
2003
- 2003-09-18 TR TR2003/01552A patent/TR200301552A1/en unknown
-
2004
- 2004-09-16 WO PCT/TR2004/000039 patent/WO2005025564A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2005025564A1 (en) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0954314T3 (en) | Dosage forms for ameliorating male erectile dysfunction | |
SE0001899D0 (en) | New compounds | |
NO20062504L (en) | Compositions and dosage forms for improved absorption | |
TW200603787A (en) | Topical preparations containing ambroxol | |
AR037490A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES | |
EA200700049A1 (en) | PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL | |
NO20025621D0 (en) | Sustained release pharmaceutical composition for parenteral administration of hydrophilic compounds | |
NO20024309D0 (en) | Intradermal penetrants for topical local anesthetic administration | |
BR9712523A (en) | New heterocyclyl-substituted pyrazole derivatives | |
BR0112054A (en) | Micelle-forming composition, and methods for administration and protection of a therapeutic agent | |
DE50203456D1 (en) | DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS | |
EA200901393A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE | |
BRPI0414428A (en) | pharmaceutical compositions | |
RS50768B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
ATE292453T1 (en) | ANTIVIRAL DRUG | |
HUP0402178A2 (en) | Pharmaceutical composition comprising a 5 hti receptor agonist | |
SE0301699D0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
MY141012A (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
BRPI0412430A (en) | zot and zonulin receptor agonist polypeptide | |
BR0113165A (en) | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods | |
TR200200473T2 (en) | Rar selective retinoid agonists. | |
TR200301553A1 (en) | New oral pharmaceutical formulations containing irbesartan active ingredient | |
HUP0203148A2 (en) | Orally distintegrating composition comprising mirtazapine | |
DE50005082D1 (en) | Process for the production of powdery solubilizing aids for solid pharmaceutical dosage forms | |
TR200301552A1 (en) | Novel oral pharmacological formulations of rofecoxib. |